Open-source Artificial Pancreas Systems Are Safe and Effective When Supported In-clinic : Outcomes in 248 Consecutive Type 1 Diabetes Clients
Copyright © 2023 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved..
OBJECTIVE: Our aim in this study was to determine the safety, glycemia, and quality of life (QoL) associated with in-clinic installation and management of supported open-source artificial pancreas systems (SOSAPS) in type 1 diabetes (T1D).
METHODS: This investigation is a retrospective cohort study of consecutive SOSAPS users at a Canadian diabetes centre. SOSAPS were offered to all moderately tech-savvy T1D clients on sensor-augmented multiple daily injection or pump, able to pay for hardware, and willing to sign a consent and waiver document. SOSAPS were installed and maintained by clinic staff at no cost to clients. iPhone users were assigned to either Loop (n=108) or iPhone artificial pancreas systems (iAPS; n=114) and Android users to Android-type APS (n=24). Outcomes included severe hypoglycemia and diabetic ketoacidosis (DKA), time in range (TIR) 4.0 to 10.0 mmol/L, time below range (TBR) <4 mmol/L, glucose management indicator (GMI), mean sensor glucose (MSG), change in glycated hemoglobin (A1C), and QoL.
RESULTS: Two hundred forty-eight subjects (131 males, 117 females), with a mean age of 36 years and diabetes duration of 21 years, experienced 3 episodes of severe hypoglycemia and no DKA over a follow-up of 17 months. TIR rose by 16%, from 64% to 80% (p<0.0001); TBR fell by 1.0%, from 3.5% to 2.5% (p=0.001); MSG fell from 9.0 to 8.1 mmol/L (p<0.001); GMI fell from 7.3% to 6.7% (p<0.001); and A1C fell from 7.2% to 6.7% (p<0.0001). QoL scores were healthy before and improved after SOSAPS.
CONCLUSIONS: Clients with T1D using SOSAPS and supported with no-cost care to the client (software, technology, and physician/physician assistant) safely achieved improved TIR, GMI, A1C, and QoL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Canadian journal of diabetes - 48(2024), 1 vom: 16. Feb., Seite 59-65.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Samuel, Praveen [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcjd.2023.09.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362959749 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362959749 | ||
| 003 | DE-627 | ||
| 005 | 20240219231901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcjd.2023.09.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM362959749 | ||
| 035 | |a (NLM)37802366 | ||
| 035 | |a (PII)S1499-2671(23)00221-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Samuel, Praveen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Open-source Artificial Pancreas Systems Are Safe and Effective When Supported In-clinic |b Outcomes in 248 Consecutive Type 1 Diabetes Clients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: Our aim in this study was to determine the safety, glycemia, and quality of life (QoL) associated with in-clinic installation and management of supported open-source artificial pancreas systems (SOSAPS) in type 1 diabetes (T1D) | ||
| 520 | |a METHODS: This investigation is a retrospective cohort study of consecutive SOSAPS users at a Canadian diabetes centre. SOSAPS were offered to all moderately tech-savvy T1D clients on sensor-augmented multiple daily injection or pump, able to pay for hardware, and willing to sign a consent and waiver document. SOSAPS were installed and maintained by clinic staff at no cost to clients. iPhone users were assigned to either Loop (n=108) or iPhone artificial pancreas systems (iAPS; n=114) and Android users to Android-type APS (n=24). Outcomes included severe hypoglycemia and diabetic ketoacidosis (DKA), time in range (TIR) 4.0 to 10.0 mmol/L, time below range (TBR) <4 mmol/L, glucose management indicator (GMI), mean sensor glucose (MSG), change in glycated hemoglobin (A1C), and QoL | ||
| 520 | |a RESULTS: Two hundred forty-eight subjects (131 males, 117 females), with a mean age of 36 years and diabetes duration of 21 years, experienced 3 episodes of severe hypoglycemia and no DKA over a follow-up of 17 months. TIR rose by 16%, from 64% to 80% (p<0.0001); TBR fell by 1.0%, from 3.5% to 2.5% (p=0.001); MSG fell from 9.0 to 8.1 mmol/L (p<0.001); GMI fell from 7.3% to 6.7% (p<0.001); and A1C fell from 7.2% to 6.7% (p<0.0001). QoL scores were healthy before and improved after SOSAPS | ||
| 520 | |a CONCLUSIONS: Clients with T1D using SOSAPS and supported with no-cost care to the client (software, technology, and physician/physician assistant) safely achieved improved TIR, GMI, A1C, and QoL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clinical outcomes | |
| 650 | 4 | |a closed-loop systems | |
| 650 | 4 | |a diabète de type 1 | |
| 650 | 4 | |a glycemic outcomes | |
| 650 | 4 | |a indice glycémique | |
| 650 | 4 | |a initiatives dirigées par le patient | |
| 650 | 4 | |a patient-driven initiatives | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a qualité de vie | |
| 650 | 4 | |a résultats cliniques | |
| 650 | 4 | |a systèmes en boucle fermée | |
| 650 | 4 | |a type 1 diabetes | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Khan, Nabeel |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Gerri |e verfasserin |4 aut | |
| 700 | 1 | |a Skobkarev, Sergey |e verfasserin |4 aut | |
| 700 | 1 | |a Mammon, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Hawke, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Weissinger, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Elliott, Tom |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Canadian journal of diabetes |d 2008 |g 48(2024), 1 vom: 16. Feb., Seite 59-65.e1 |w (DE-627)NLM231201249 |x 2352-3840 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2024 |g number:1 |g day:16 |g month:02 |g pages:59-65.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcjd.2023.09.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2024 |e 1 |b 16 |c 02 |h 59-65.e1 | ||